Phase III Significance Study of KRP-AB1102F DPI

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2013
INTERVENTION: Intervention name : KRP‐AB1102F DPI Dosage And administration of the intervention : Inhalation, Twice daily Control intervention name : Aclidinium Bromide(KRP‐AB1102 DPI) Dosage And administration of the control intervention : Inhalation, Twice daily CONDITION: COPD PRIMARY OUTCOME: Trough FEV1 SECONDARY OUTCOME: 1h Post dose FEV1 INCLUSION CRITERIA: COPD patients with post‐bronchodilator FEV1 between 30 and 80 % of predicted
Epistemonikos ID: f3d9ed0e24c9278eae72bbc149b312e87233dfa5
First added on: Aug 22, 2024